会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Hands-free camera holder
    • 免提相机支架
    • US08206045B2
    • 2012-06-26
    • US12785289
    • 2010-05-21
    • Theresa M. SweeneyMark Whittaker
    • Theresa M. SweeneyMark Whittaker
    • G03B17/00H04N5/225
    • G03B17/561F16M13/04
    • Embodiments of hands-free camera holders according to the present disclosure can enable a user to obtain the exact picture they want by giving them complete control of the camera position. A hands-free camera holder can include a camera support member, e.g., a platform, that is connected by way of an adjustable frame. In optional embodiments, the user can connect to the frame by way or a collar/harness. By using a switch, or trigger means, that is connected to the camera, to take the picture, the framing of the picture is not disturbed, whether activated by the user or an assistant. The separate switch concept/means can also enable individuals with disabilities to use other parts of their body to operate the camera. Using adaptive technology, any reliable movement can be used as a trigger for the camera.
    • 根据本公开的免提相机保持器的实施例可以使用户能够通过给予他们完全控制相机位置来获得他们想要的确切图像。 免提相机支架可以包括通过可调节框架连接的相机支撑构件,例如平台。 在可选实施例中,用户可以通过方式或衣领/线束连接到框架。 通过使用连接到相机的开关或触发装置拍摄照片,图像的成帧不会受到用户或助手激活的影响。 单独的开关概念/手段还可以使残疾人能够使用身体的其他部分来操作相机。 使用自适应技术,任何可靠的运动都可以用作相机的触发器。
    • 2. 发明申请
    • HANDS-FREE CAMERA HOLDER
    • 无手掌相机
    • US20110052178A1
    • 2011-03-03
    • US12785289
    • 2010-05-21
    • Theresa M. SweeneyMark Whittaker
    • Theresa M. SweeneyMark Whittaker
    • G03B17/00
    • G03B17/561F16M13/04
    • Embodiments of hands-free camera holders according to the present disclosure can enable a user to obtain the exact picture they want by giving them complete control of the camera position. A hands-free camera holder can include a camera support member, e.g., a platform, that is connected by way of an adjustable frame. In optional embodiments, the user can connect to the frame by way or a collar/harness. By using a switch, or trigger means, that is connected to the camera, to take the picture, the framing of the picture is not disturbed, whether activated by the user or an assistant. The separate switch concept/means can also enable individuals with disabilities to use other parts of their body to operate the camera. Using adaptive technology, any reliable movement can be used as a trigger for the camera.
    • 根据本公开的免提相机保持器的实施例可以使用户能够通过给予他们完全控制相机位置来获得他们想要的确切图像。 免提相机支架可以包括通过可调节框架连接的相机支撑构件,例如平台。 在可选实施例中,用户可以通过方式或衣领/线束连接到框架。 通过使用连接到相机的开关或触发装置拍摄照片,图像的成帧不会受到用户或助手激活的影响。 单独的开关概念/手段还可以使残疾人能够使用身体的其他部分来操作相机。 使用自适应技术,任何可靠的运动都可以用作相机的触发器。
    • 3. 发明授权
    • Compounds having CRTH2 antagonist activity
    • 具有CRTH2拮抗活性的化合物
    • US08563536B2
    • 2013-10-22
    • US13017860
    • 2011-01-31
    • Richard Edward ArmerEric Roy PettipherMark WhittakerGraham Michael WynneJulia VileFrank Schroer
    • Richard Edward ArmerEric Roy PettipherMark WhittakerGraham Michael WynneJulia VileFrank Schroer
    • A61K31/70A61K31/56A61K31/50A61K31/47A61K31/44
    • A61K31/4439A61K31/47A61K45/06C07D401/06
    • Compounds of general formula (II) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(═O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C═O)R6)2; m is 1 or 2; n is 1-4; X is OR5 or N(R5)2; R5 is hydrogen or methyl; and R6 is C1-C18 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.
    • 通式(II)的化合物,其中W是氯或氟; R 1是任选被一个或多个选自卤素,-CN,-C 1 -C 6烷基,-SOR 3,-SO 2 R 3,-SO 2 N(R 2)2,-N(R 2)2,-NR 2 C(O)R 3 ,-CO 2 R 2,-CONR 2 R 3,-NO 2,-OR 2,-SR 2,-O(CH 2)pOR 2或-O(CH 2)p O(CH 2)q OR 2,其中每个R 2独立地是氢,-C 1 -C 6烷基, C8环烷基,芳基或杂芳基; 每个R 3独立地是-C 1 -C 6烷基,-C 3 -C 8环烷基,芳基或杂芳基; p和q各自独立地为1至3的整数; 芳基,(CH2)mOC(= O)C1-C6烷基,((CH2)mO)nCH2CH2X,(CH2)mN(R5)2或CH ((CH 2)m O(C = O)R 6)2; m为1或2; n为1-4; X为OR 5或N(R 5)2; R5是氢或甲基; R6为C1-C18烷基; 其药学上可接受的盐,水合物,溶剂合物,复合物或前药可用于口服给药的组合物中,用于治疗过敏性疾病如哮喘,过敏性鼻炎和特应性皮炎。
    • 4. 发明授权
    • Compounds having CRTH2 antagonist activity
    • 具有CRTH2拮抗活性的化合物
    • US08536158B2
    • 2013-09-17
    • US13014314
    • 2011-01-26
    • Richard Edward ArmerEric Roy PettipherMark WhittakerGraham Michael WynneJulia VileFrank Schroer
    • Richard Edward ArmerEric Roy PettipherMark WhittakerGraham Michael WynneJulia VileFrank Schroer
    • A61K31/70A61K31/56A61K31/50A61K31/47A61K31/44
    • A61K31/4439A61K31/47A61K45/06C07D401/06
    • Compounds of general formula (I) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(═O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C═O)R6)2; m is 1 or 2; n is 1-4; X is OR5 or N(R5)2; R5 is hydrogen or methyl; and R6 is C1-C18 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.
    • 通式(I)的化合物,其中W是氯或氟; R 1是任选被一个或多个选自卤素,-CN,-C 1 -C 6烷基,-SOR 3,-SO 2 R 3,-SO 2 N(R 2)2,-N(R 2)2,-NR 2 C(O)R 3 ,-CO 2 R 2,-CONR 2 R 3,-NO 2,-OR 2,-SR 2,-O(CH 2)pOR 2或-O(CH 2)p O(CH 2)q OR 2,其中每个R 2独立地是氢,-C 1 -C 6烷基, C8环烷基,芳基或杂芳基; 每个R 3独立地是-C 1 -C 6烷基,-C 3 -C 8环烷基,芳基或杂芳基; p和q各自独立地为1至3的整数; 芳基,(CH2)mOC(= O)C1-C6烷基,((CH2)mO)nCH2CH2X,(CH2)mN(R5)2或CH ((CH 2)m O(C = O)R 6)2; m为1或2; n为1-4; X为OR 5或N(R 5)2; R5是氢或甲基; R6为C1-C18烷基; 其药学上可接受的盐,水合物,溶剂合物,复合物或前药可用于口服给药的组合物中,用于治疗过敏性疾病如哮喘,过敏性鼻炎和特应性皮炎。
    • 6. 发明申请
    • Compounds Having CRTH2 Antagonist Activity
    • 具有CRTH2拮抗作用的化合物
    • US20100063103A1
    • 2010-03-11
    • US12625497
    • 2009-11-24
    • Richard Edward ARMEREric Roy PettipherMark WhittakerGraham Michael WynneJulia VileFrank Schroer
    • Richard Edward ARMEREric Roy PettipherMark WhittakerGraham Michael WynneJulia VileFrank Schroer
    • A61K31/4439C07D401/06A61P37/08
    • A61K31/4439A61K31/47A61K45/06C07D401/06
    • Compounds of general formula (I) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(═O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C═O)R6)2; m is 1 or 2; n is 1-4; X is OR5 or N(R5)2; R5 is hydrogen or methyl; and R6 is C1-C18 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.
    • 通式(I)的化合物,其中W是氯或氟; R 1是任选被一个或多个选自卤素,-CN,-C 1 -C 6烷基,-SOR 3,-SO 2 R 3,-SO 2 N(R 2)2,-N(R 2)2,-NR 2 C(O)R 3 ,-CO 2 R 2,-CONR 2 R 3,-NO 2,-OR 2,-SR 2,-O(CH 2)pOR 2或-O(CH 2)p O(CH 2)q OR 2,其中每个R 2独立地是氢,-C 1 -C 6烷基, C8环烷基,芳基或杂芳基; 每个R 3独立地是-C 1 -C 6烷基,-C 3 -C 8环烷基,芳基或杂芳基; p和q各自独立地为1至3的整数; 芳基,(CH2)mOC(= O)C1-C6烷基,((CH2)mO)nCH2CH2X,(CH2)mN(R5)2或CH ((CH 2)m O(C = O)R 6)2; m为1或2; n为1-4; X为OR 5或N(R 5)2; R5是氢或甲基; R6为C1-C18烷基; 其药学上可接受的盐,水合物,溶剂合物,复合物或前药可用于口服给药的组合物中,用于治疗过敏性疾病如哮喘,过敏性鼻炎和特应性皮炎。
    • 7. 发明申请
    • Glyoxalase inhibitors
    • 乙二醛酶抑制剂
    • US20070015799A1
    • 2007-01-18
    • US10556901
    • 2004-05-14
    • Mark AshtonAlan DavidsonRussell ThomasMark Whittaker
    • Mark AshtonAlan DavidsonRussell ThomasMark Whittaker
    • A61K31/4436A61K31/44A61K31/381
    • C07D405/04A61K31/10A61K31/381A61K31/44A61K31/4436C07C323/62C07D213/85C07D217/26C07D409/04C07D409/14
    • This invention relates to compounds of formula (I) which are glyoxalase I inhibitors, pharmaceutical salts or compositions comprising such compounds, and the use of such compositions and compounds to treat various conditions alleviated by the inhibition of glyoxalase 1. Wherein X is N or CH. R2 is H, CF3; or optionally substituted C5-6 aryl, C3-7 cycloalkyl, C5-7 heterocyclyl. R3 is H; or optionally substituted C5-6 aryl, C3-7 cycloalkyl, C5-7 heterocyclyl. Alternatively R2 and R3 together form an optionally substituted C3-4alkylene group wherein L3 and L4 are single bonds thus forming a C5-6 ring fused with the aromatic ring to which L3 and L4 are attached. L3 and L4 are independently selected from a single bond, optionally substituted C1-4 alkylene, -L9YN(OH)C(═O)L10- and -L9C(═O)N(OH)YL10-, wherein L9 and L10 are independently selected from optionally substituted C1-4 alkylene, C5-6 arylene, C1-4 alkylene-C5-6arylene and a single bond, wherein Y is NH or a single bond.
    • 本发明涉及作为乙二醛酶I抑制剂的式(I)化合物,包含这些化合物的药物盐或组合物,以及这些组合物和化合物用于治疗通过抑制乙二醛酶1减轻的各种病症的用途。其中X是N或CH 。 R 2是H,CF 3 N; 或任选取代的C 5-6芳基,C 3-7环烷基,C 5-7杂环基。 R 3是H; 或任选取代的C 5-6芳基,C 3-7环烷基,C 5-7杂环基。 或者R 2和R 3一起形成任选取代的C 3-4亚烷基,其中L 3和L 3 因此形成与L 3和L 4的芳环稠合的C 5〜6环, SUP>连接。 L 3和L 4独立地选自单键,任选取代的C 1-4亚烷基,-L 9, SUP-YN(OH)C(-O)L 10 - 和-L 9 C( - )N(OH)Y L 10 - ,其中L 9和L 10独立地选自任选取代的C 1-4 - 亚烷基,C 5-6 - 亚芳基,C 1-4亚烷基-C 5-6亚芳基和单键,其中Y是NH或单键。